April 25, 2017
Merck Sharp & Dohme Corp. and PDL BioPharma Inc. have called a truce in a patent infringement dispute over Merck's cancer drug Keytruda, as the companies announced Monday that Merck will pay $19.5 million to license related patent rights and dismiss the case.
January 26, 2016
PDL BioPharma Inc. blasted Merck Sharp & Dohme Corp. over cancer drug Keytruda in New Jersey federal court Monday, alleging the medication infringes on the company's patent related to a type of antibody used in treatments that attack cancer cells without damaging healthy cells.